Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Guadecitabine in Advanced Kidney Cancer
NCT03308396Phase 2Active, not recruiting
- Start
- Dec 2017
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, guadecitabine in clear cell renal cell carcinoma (ccRCC). Started Dec 2017; status: active, not recruiting.
02
Drugs
durvalumabguadecitabine
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03308396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308396.